Browse All

Current Filters

CLEAR FILTER x

TITLE

Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study

Author:Bar-Or, Amit   Oh, Jiwon   Giovannoni, Gavin   Sormani, Maria Pia   Weber, Martin S.   Stoll, Sharon   Nicholas, Jacqueline A.   Büdingen, H.-Christian von   Lopez, Jon   Roberts, Louise   Triyatni, Miriam   Qi, Qi   Ratchford, John N.   Napieralski, Julie   Goodyear, Alexandra   Hauser, Stephen L.   Kappos, Ludwig   

Session Name:S40: Multiple Sclerosis: Clinical Trials/Science and Real-world Evidence  

Topic:Multiple Sclerosis  

Program Number:S40.004  

Author Institution:Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA  St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada  Queen Mary University of London, London, UK, London, United Kingdom  University of Genoa, Genoa, Italy, Genoa, Italy  Institute of Neuropathology and Department of Neurology, University Medical Center and Fraunhofer Institute for Translational Medicine and Pharmacology, Göttingen, Germany, Göttingen, Germany  Advocare Stoll Medical Group, Philadelphia, PA, USA, Philadelphia, PA  OhioHealth Multiple Sclerosis Centre, Riverside Methodist Hospital, Columbus, OH, USA, Columbus, OH  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Genentech, Inc., South San Francisco, CA, USA, South San Francisco, CA  University of California San Francisco, San Francisco, CA, USA, San Francisco, CA  University Hospital and University Basel, Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Basel, Switzerland, Basel, Switzerland  

Efficacy and Safety of Ocrelizumab Compared With Fingolimod in Pediatric-onset Relapsing-remitting MS: Results of the Phase III OPERETTA Two Study

Author:Banwell, Brenda   Kotulska, Katarzyna   Rostásy, Kevin   Deiva, Kumaran   Sato, Henry   Filippi, Massimo   Chitnis, Tanuja   Sormani, Maria Pia   Krupp, Lauren   Bar-Or, Amit   Evershed, Joanna   El Azzouzi, Bouchra   Wang, Qing   Lin, Chien-Ju   Hogea, Alexandra   Schneble, Hans-Martin   Manlius, Corinne   Waubant, Emmanuelle   

Session Name:S40: Multiple Sclerosis: Clinical Trials/Science and Real-world Evidence  

Topic:Multiple Sclerosis  

Program Number:S40.005  

Author Institution:Department of Pediatrics, Johns Hopkins University, Baltimore, MD, USA, Baltimore, MD  Department of Neurology and Epileptology, The Children’s Memorial Health Institute, Warsaw, Poland, Warsaw, Poland  Pediatric Neurology at Children's Hospital, Datteln, Germany, Datteln, Germany  Department of Pediatrics Neurology, Bicêtre Hospital, Le Kremlin-Bicêtre, France and Paris Sud-Saclay University, Le Kremlin-Bicêtre, France, Le Kremlin-Bicêtre, France  Neurological Institute of Curitiba, Curitiba, PR, Brazil, Curitiba, PR, Brazil  Neuroimaging Research Unit, Division of Neuroscience, Neurology Unit, Neurorehabilitation Unit and Neurophysiology Service, IRCCS San Raffaele Scientific Institute, and Vita-Salute San Raffaele University, Milan, Italy, Milan, Italy  Department of Pediatric Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Boston, MA  DISSAL, University of Genoa, Genoa, Italy, Genoa, Italy  Department of Neurology, NYU Langone Health, New York, NY, USA, New York, NY  Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA  Roche Products Ltd, Welwyn Garden City, UK, Welwyn Garden City, United Kingdom  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Neurology, University of California San Francisco, San Francisco, CA, USA, San Francisco, CA  

Efficacy and Safety of Tolebrutinib Versus Placebo in Primary Progressive Multiple Sclerosis: Results from the Phase Three PERSEUS Trial

Author:Fox, Robert   Bar-Or, Amit   Vermersch, Patrick   Oreja Guevara, Celia   Traboulsee, Anthony   Giovannoni, Gavin   Syed, Sana   Sun, Furong   Salloum, Naji   Turner, Timothy   Wallstroem, Erik   Reich, Daniel   

Session Name:PL6: Contemporary Clinical Issues Plenary Session  

Topic:Multiple Sclerosis  

Program Number:PL6.003  

Author Institution:Cleveland Clinic, Cleveland, OH  University of Pennsylvania, Philadelphia, PA  University of Lille, Lille, France  Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain  University of British Columbia, Vancouver, BC, Canada  Queen Mary University London, London, United Kingdom  Sanofi , Cambridge, MA  Sanofi, Morristown, NJ  Sanofi, CHILLY-MAZARIN, France  Sanofi, Cambridge, MA  Translational Neuroradiology Section, National Institutes of Health, Bethesda, MD  

The Gut Microbiome in Pediatric-onset Acquired Demyelinating Syndromes by Myelin Oligodendrocyte Glycoprotein Antibody Status

Author:Tsai, Wendy   Zhu, Feng   Bar-Or, Amit   Bernstein, Charles   Bonner, Christine   Graham, Morag   Marrie, Ruth-Ann   Mirza, Ali   O'Mahony, Julia   Yeh, E. Ann   Banwell, Brenda   Waubant, Emmanuelle   Tremlett, Helen   

Session Name:P3: Multiple Sclerosis: NMOSD, MOGAD, and Other Mimickers of MS 1  

Topic:Multiple Sclerosis  

Program Number:P3.008  

Author Institution:University of Toronto, Toronto, ON, Canada  University of British Columbia and the Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, Canada  University of Pennsylvania, Philadelphia, PA  University of Manitoba, Winnipeg, MB, Canada  Public Health Agency of Canada, Winnipeg, MB, Canada  Dalhousie University, Halifax, NS, Canada  Case Western Reserve University, Cleveland, OH  The Hospital for Sick Children, Toronto, ON, Canada  Johns Hopkins University, Baltimore, MD  University of California San Francisco, San Francisco, CA  

GA Depot (Long-acting IM Glatiramer Acetate) and its Impact on EDSS in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS)

Author:Miller, Aaron   Popper, Laura   Berger, Joseph   Bar-Or, Amit   Zivadinov, Robert   Kolb, Hadar   Karni, Arnon   Almog, Ornit   kimelman, nadav   Rubnov, Shai   Danon, Uri   Marom, Ehud   

Session Name:P7: Multiple Sclerosis: Clinical Trials 1  

Topic:Multiple Sclerosis  

Program Number:P7.002  

Author Institution:Mt Sinai School Of Med, New York, NY  Mapi Pharma Ltd., Ness Ziona, Israel  University of Pennsylvania, PA  University of Pennsylvania, Philadelphia, PA  University at Buffalo, NY  Tel Aviv Medical Center, Israel  Mapi Pharma, Nez Ziona, Israel  Mapi Pharma, Israel